VAP - Ventilator Associated Pneumonia
16
5
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (16)
EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study)
Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS
Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia
Effect of the Aspiration Care Bundle on Preventing VAP
Oral Care Layered Enhancement for Improved Oral Hygiene in Intensive Care Units
HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array
LUNG INFECTION in ICU (LUNG-I3)
Ventilator-associated Pneumonia (VAP) Diagnostic Stewardship Trial
Physiological Effects and Safety of Continuous High-frequency Oscillatory Ventilation in Mechanical Ventilation Patients
Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation
Efficiency and Safety of the Prolonged Use of Heat and Moisture Exchangers in ICU
Performance Study of Targeted Sequencing Technology for VAP
Microbiological Profile of VAP Patients in Respiratory ICU
Impact of Teeth Brushing in Ventilated COVID-19 Patients.
Effect of Statin Therapy on Mortality in Patients With Ventilator Associated Pneumonia
The Effectiveness of the Modified Bundle in the Prevention of VAP.